新诺威(300765) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥341,185,765.18, a decrease of 1.29% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2021 was ¥80,978,666.20, an increase of 4.22% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥77,752,688.84, reflecting a year-on-year increase of 9.59%[3] - Total operating revenue for Q3 2021 was CNY 1,048,618,549.78, a slight increase from CNY 1,032,894,694.22 in Q3 2020, representing a growth of approximately 1.3%[18] - Net profit for Q3 2021 was CNY 244,267,982.52, down from CNY 257,207,659.19 in Q3 2020, reflecting a decline of approximately 5.0%[19] - The company reported a total comprehensive income of CNY 243,805,553.55 for Q3 2021, compared to CNY 256,836,928.28 in Q3 2020, a decrease of approximately 5.1%[19] Assets and Liabilities - Total assets at the end of Q3 2021 reached ¥3,127,645,936.40, representing a growth of 5.85% from the end of the previous year[4] - The company's equity attributable to shareholders increased to ¥2,880,098,554.44, up 7.54% from the previous year[4] - The total assets of the company as of September 30, 2021, were approximately RMB 3.13 billion, representing an increase of 5.8% from RMB 2.95 billion at the end of 2020[15] - The total liabilities decreased to CNY 238,940,831.66 from CNY 268,003,205.40, a reduction of about 10.8%[18] - Total equity increased to CNY 2,888,705,104.74 from CNY 2,686,899,551.19, representing an increase of approximately 7.5%[18] Cash Flow - Cash flow from operating activities for the year-to-date was ¥169,991,542.05, down 36.81% compared to the same period last year[9] - The net cash flow from operating activities for the current period is ¥169,991,542.05, a decrease of 36.7% compared to ¥269,027,400.04 in the previous period[21] - The total cash inflow from investment activities is ¥1,087,730,806.55, down 55.2% from ¥2,428,915,126.43 in the previous period[22] - The cash inflow from sales of goods and services is ¥1,006,444,586.98, a slight decrease from ¥1,064,216,590.00 in the previous period[21] - The total cash outflow from operating activities is ¥907,329,478.18, an increase from ¥829,420,708.20 in the previous period[21] Research and Development - Research and development expenses increased by 43.26% year-on-year, amounting to ¥11,907,685.12[8] - Research and development expenses rose to CNY 11,907,685.12 from CNY 8,312,189.41, indicating an increase of about 43.5%[18] Investment and Acquisitions - The company plans to acquire 100% equity of Shijiazhuang Santai Glucose Co., Ltd. from its controlling shareholder, which will become a wholly-owned subsidiary upon completion of the transaction[13] - The company intends to raise funds not exceeding 100% of the transaction price through a private placement to support the acquisition[13] - The company is currently undergoing auditing and evaluation processes related to the acquisition, with further approvals required from the board and regulatory bodies[13] - The company has identified potential risks associated with the approval process for the acquisition, which may affect the timeline of the transaction[13] Inventory and Receivables - The company experienced a significant increase in accounts receivable by 41.58% compared to the end of last year, amounting to ¥207,095,303.01[6] - The accounts receivable increased to RMB 207.10 million, up from RMB 146.27 million, indicating a growth of 41.5%[14] - The company's inventory increased to RMB 173.76 million, a significant rise of 56.5% compared to RMB 110.99 million in the previous year[15]